125 related articles for article (PubMed ID: 35019195)
1. The key role of organic anion transporter 3 in the drug-drug interaction between tranilast and methotrexate.
Wang J; Yuan W; Shen Q; Wu Q; Jiang Z; Wu W; Zhang L; Huang X
J Biochem Mol Toxicol; 2022 Apr; 36(4):e22983. PubMed ID: 35019195
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Methotrexate Uptake via Organic Anion Transporters OAT1 and OAT3 by Glucuronides of Nonsteroidal Anti-inflammatory Drugs.
Iwaki M; Shimada H; Irino Y; Take M; Egashira S
Biol Pharm Bull; 2017; 40(6):926-931. PubMed ID: 28566636
[TBL] [Abstract][Full Text] [Related]
3. Interaction of immunosuppressive drugs with human organic anion transporter (OAT) 1 and OAT3, and multidrug resistance-associated protein (MRP) 2 and MRP4.
El-Sheikh AA; Greupink R; Wortelboer HM; van den Heuvel JJ; Schreurs M; Koenderink JB; Masereeuw R; Russel FG
Transl Res; 2013 Dec; 162(6):398-409. PubMed ID: 24036158
[TBL] [Abstract][Full Text] [Related]
4. P-gp, MRP2 and OAT1/OAT3 mediate the drug-drug interaction between resveratrol and methotrexate.
Jia Y; Liu Z; Wang C; Meng Q; Huo X; Liu Q; Sun H; Sun P; Yang X; Ma X; Liu K
Toxicol Appl Pharmacol; 2016 Sep; 306():27-35. PubMed ID: 27377006
[TBL] [Abstract][Full Text] [Related]
5. MDR1 and OAT1/OAT3 mediate the drug-drug interaction between puerarin and methotrexate.
Liu Q; Wang C; Meng Q; Huo X; Sun H; Peng J; Ma X; Sun P; Liu K
Pharm Res; 2014 May; 31(5):1120-32. PubMed ID: 24242937
[TBL] [Abstract][Full Text] [Related]
6. Effect of methotrexate treatment on expression levels of multidrug resistance protein 2, breast cancer resistance protein and organic anion transporters Oat1, Oat2 and Oat3 in rats.
Shibayama Y; Ushinohama K; Ikeda R; Yoshikawa Y; Motoya T; Takeda Y; Yamada K
Cancer Sci; 2006 Nov; 97(11):1260-6. PubMed ID: 16925582
[TBL] [Abstract][Full Text] [Related]
7. Puerarin improves methotrexate-induced renal damage by up-regulating renal expression of Oat1 and Oat3 in vivo and in vitro.
Liu Q; Liu Z; Huo X; Wang C; Meng Q; Sun H; Sun P; Peng J; Ma X; Liu K
Biomed Pharmacother; 2018 Jul; 103():915-922. PubMed ID: 29710508
[TBL] [Abstract][Full Text] [Related]
8. Quantitative evaluation of the drug-drug interactions between methotrexate and nonsteroidal anti-inflammatory drugs in the renal uptake process based on the contribution of organic anion transporters and reduced folate carrier.
Nozaki Y; Kusuhara H; Endou H; Sugiyama Y
J Pharmacol Exp Ther; 2004 Apr; 309(1):226-34. PubMed ID: 14722319
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of
Parvez MM; Shin HJ; Jung JA; Shin JG
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223391
[No Abstract] [Full Text] [Related]
10. In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug-drug interaction with methotrexate.
Elsby R; Fox L; Stresser D; Layton M; Butters C; Sharma P; Smith V; Surry D
Eur J Pharm Sci; 2011 May; 43(1-2):41-9. PubMed ID: 21440623
[TBL] [Abstract][Full Text] [Related]
11. Differential interactions of the β-lactam cloxacillin with human renal organic anion transporters (OATs).
Lalanne S; Le Vée M; Lemaitre F; Le Corre P; Verdier MC; Fardel O
Fundam Clin Pharmacol; 2020 Aug; 34(4):476-483. PubMed ID: 32100322
[TBL] [Abstract][Full Text] [Related]
12. Proton pump inhibitors inhibit methotrexate transport by renal basolateral organic anion transporter hOAT3.
Chioukh R; Noel-Hudson MS; Ribes S; Fournier N; Becquemont L; Verstuyft C
Drug Metab Dispos; 2014 Dec; 42(12):2041-8. PubMed ID: 25239859
[TBL] [Abstract][Full Text] [Related]
13. Coadministration of vindesine with high-dose methotrexate therapy increases acute kidney injury via BCRP, MRP2, and OAT1/OAT3.
Huang C; Xia F; Xue L; Liu L; Bian Y; Jin Z; Miao L
Cancer Chemother Pharmacol; 2020 Feb; 85(2):433-441. PubMed ID: 31691080
[TBL] [Abstract][Full Text] [Related]
14. Drug Metabolites Potently Inhibit Renal Organic Anion Transporters, OAT1 and OAT3.
Zou L; Matsson P; Stecula A; Ngo HX; Zur AA; Giacomini KM
J Pharm Sci; 2021 Jan; 110(1):347-353. PubMed ID: 32910949
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of possible pharmacokinetic interaction between methotrexate and proton pump inhibitors in rats.
Ueda H; Narumi K; Sato Y; Furugen A; Kobayashi M; Iseki K
Pharmacol Rep; 2020 Oct; 72(5):1426-1432. PubMed ID: 32671657
[TBL] [Abstract][Full Text] [Related]
16. Organic anion transporter 3- and organic anion transporting polypeptides 1B1- and 1B3-mediated transport of catalposide.
Jeong HU; Kwon M; Lee Y; Yoo JS; Shin DH; Song IS; Lee HS
Drug Des Devel Ther; 2015; 9():643-53. PubMed ID: 25653502
[TBL] [Abstract][Full Text] [Related]
17. Renal uptake of substrates for organic anion transporters Oat1 and Oat3 and organic cation transporters Oct1 and Oct2 is altered in rats with adenine-induced chronic renal failure.
Komazawa H; Yamaguchi H; Hidaka K; Ogura J; Kobayashi M; Iseki K
J Pharm Sci; 2013 Mar; 102(3):1086-94. PubMed ID: 23280877
[TBL] [Abstract][Full Text] [Related]
18. Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.
Rizk ML; Houle R; Chan GH; Hafey M; Rhee EG; Chu X
Antimicrob Agents Chemother; 2014; 58(3):1294-301. PubMed ID: 24295974
[TBL] [Abstract][Full Text] [Related]
19. Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3.
Narumi K; Sato Y; Kobayashi M; Furugen A; Kasashi K; Yamada T; Teshima T; Iseki K
Biopharm Drug Dispos; 2017 Dec; 38(9):501-508. PubMed ID: 28801980
[TBL] [Abstract][Full Text] [Related]
20. Organic anion transporter 3 (OAT3)-mediated transport of dicaffeoylquinic acids and prediction of potential drug-drug interaction.
Wang Y; Ren J; Sun Q; Zhang Z; Lin Y; Deng S; Wang C; Huo X; Sun C; Tian X; Zhang B; Feng L; Ma X
Eur J Pharm Sci; 2019 May; 133():95-103. PubMed ID: 30928510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
